Event Recordings

Day 1  |  Day 2

Day 2: Tuesday, April 26, 2022

Day 2 Introduction & Welcome

Joseph Wu, M.D., Ph.D.
Director, Stanford Cardiovascular Institute
Simon H. Stertzer, M.D., Professor of Medicine and Radiology

Session VI: Research Development III

Moderator: Kathleen Giacomini, PhD | Co-Moderator: Kuldev Singh, MD

Full Session

Moderator: Kathleen Giacomini, Ph.D.
Prof of Bioengineering & Co-Dir UCSF-Stanford Center of Excellence in Regulatory Sciences and Innovation, UCSF

Co-Moderator: Kuldev Singh, M.D.
Professor of Ophthalmology, Stanford University School of Medicine

Speakers:
Aida Habtezion, M.D.
Chief Medical Officer and Head of Worldwide Medical & Safety, Pfizer
Translating Lessons from the Covid-19 Programs

Mathai Mammen, M.D., Ph.D.
Executive Vice President, Pharmaceuticals, R&D, Johnson& Johnson
Raising the Bar for Innovation

Peter Marks, M.D., Ph.D.
Director, Center for Biologics Evaluation and Research, U.S. FDA
Facilitating the Development and Manufacturing of COVID-19 Vaccines

Panel Discussion

Translating Lessons from the Covid-19 Programs

Aida Habtezion, MD
Chief Medical Officer and Head of Worldwide Medical & Safety, Pfizer

Raising the Bar for Innovation

Mathai Mammen, MD, PhD
Executive Vice President, Pharmaceuticals, R&D, Johnson & Johnson

Facilitating the Development and Manufacturing of COVID-19 Vaccines

Peter Marks, MD, PhD
Director, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration

Panel Discussion

Moderator: Kathleen Giacomini, Ph.D.
Prof of Bioengineering & Co-Dir UCSF-Stanford Center of Excellence in Regulatory Sciences and Innovation, UCSF

Co-Moderator: Kuldev Singh, M.D.
Professor of Ophthalmology, Stanford University School of Medicine

Speakers:

Aida Habtezion, M.D.
Chief Medical Officer and Head of Worldwide Medical & Safety, Pfizer

Mathai Mammen, M.D., Ph.D.
Executive Vice President, Pharmaceuticals, R&D, Johnson& Johnson

Peter Marks, M.D., Ph.D.
Director, Center for Biologics Evaluation and Research, U.S. FDA

Session VII : Fireside Chat with Fireside Chat with Katalin Karikó, PhD and Dean Lloyd Minor, MD

Moderator: Dean Lloyd Minor, MD | Co-Moderator: Sanjay Malhotra, PhD

Fireside Chat with Katalin Karikó, Ph.D.
Senior Vice President, BioNTech

Moderator: Dean Lloyd Minor, M.D.
Dean, Stanford School of Medicine 
 
Co-Moderator: Sanjay Malhotra, Ph.D.
Professor, Cell, Developmental & Cancer Biology; Director, Center for Experimental Therapeutics, OHSU

Session VIII: Investing in Discovery

Moderator: Amy L. Chang, MSEE | Co-Moderator: Sanjay Malhotra, PhD

Full Session

Moderator: Amy L. Chang, M.S.E.E.
Board of Directors at The Walt Disney Co, Procter & Gamble, Marqeta, and Pragma Platform

Co-Moderator: Sanjay Malhotra, Ph.D.
Professor, Cell, Developmental & Cancer Biology; Director, Center for Experimental Therapeutics, OHSU

Speakers:

Joe Jimenez, M.B.A
Co-Founder and Managing Director, Aditum Ventures
The Evolving Role of Venture Capital in the Pharma Ecosystem

David Goel
Founder & Managing General Partner, Matrix Capital Management
The Convergence of Technology and the Life Sciences

Jonathan MacQuitty, Ph.D.
Sector Head for Life Sciences, Lightspeed Ventures
A New Approach to Healthcare Investing

Margarita Chavez, J.D.
Managing Director, AbbVie Ventures
 
Panel Discussion

The Evolving Role of Venture Capital in the Pharma Ecosystem

Joe Jimenez, MBA
Aditum Ventures

The Convergence of Technology and the Life Sciences

David Goel
Founder & Managing General Partner, Matrix Capital Management

A New Approach to Healthcare Investing

Jonathan MacQuitty, PhD
Sector Head for Life Sciences, Lightspeed Ventures

Panel Discussion

Moderator: Amy L. Chang, M.S.E.E.
Board of Directors at The Walt Disney Co, Procter & Gamble, Marqeta, and Pragma Platform

Co-Moderator: Sanjay Malhotra, Ph.D.
Professor, Cell, Developmental & Cancer Biology; Director, Center for Experimental Therapeutics, OHSU

Speakers:

Joe Jimenez, M.B.A
Co-Founder and Managing Director, Aditum Ventures

David Goel
Founder & Managing General Partner, Matrix Capital Management

Jonathan MacQuitty, Ph.D.
Sector Head for Life Sciences, Lightspeed Ventures

Margarita Chavez, J.D.
Managing Director, AbbVie Ventures

Session IX: Artificial Intelligence Technologies

Moderator: James Zou, PhD | Co-Moderator: Mark Mercola, PhD

Full Session

Moderator: James Zou, Ph.D.
Assistant Professor of Biomedical Data Science and, by courtesy, of CS and of EE, Stanford University

Co-Moderator: Mark Mercola, Ph.D.
Professor of Medicine, Stanford University School of Medicine

Speakers:

Christopher Gibson, Ph.D.
Co-Founder, Chief Executive Officer, Recursion
Mapping and Navigating Biology at Scale

Daphne Koller, Ph.D.
Founder & Chief Executive Officer, Insitro
Transforming Drug Discovery using Digital Biology

Karen Akinsanya, Ph.D.
President, R&D Therapeutics, Schrödinger
Transitioning from Computer-aided and Empirical Drug Discovery to Computer-driven and Structure-based Drug Discovery
 
Panel Discussion

Mapping and Navigating Biology at Scale

Christopher Gibson, PhD
Co-Founder, Chief Executive Officer, Recursion

Transforming Drug Discovery using Digital Biology

Daphne Koller, PhD
Founder & CEO, Insitro

Transitioning from Computer-aided and Empirical Drug Discovery to Computer-driven and Structure-based Drug Discovery

Karen Akinsanya, PhD
Chief Biomedical Scientist, Schrödinger

Panel Discussion

Moderator: James Zou, Ph.D.
Assistant Professor of Biomedical Data Science and, by courtesy, of CS and of EE, Stanford University

Co-Moderator: Mark Mercola, Ph.D.
Professor of Medicine, Stanford University School of Medicine

Speakers:

Christopher Gibson, Ph.D.
Co-Founder, Chief Executive Officer, Recursion

Daphne Koller, Ph.D.
Founder & Chief Executive Officer, Insitro

Karen Akinsanya, Ph.D.
President, R&D Therapeutics, Schrödinger

Session X: Research Development IV

Moderator: Peter Kim, PhD | Co-Moderator: Kuldev Singh, MD

Full Session

Moderator: Peter Kim, Ph.D.
Virginia and D.K. Ludwig Professor of Biochemistry, Stanford University

Co-Moderator: Kuldev Singh, M.D.
Professor of Ophthalmology, Stanford University School of Medicine

Speakers:
Andrew Plump, M.D., Ph.D.
President, Research & Development, Takeda Pharmaceutical
Creating a Patient-Driven, Science-First R&D Organization

Aviv Regev, Ph.D.
Executive Vice President, Research and Early Development, Genentech

James Bradner, M.D.
President, Novartis Institutes of BioMedical Research

Merdad Parsey, M.D., Ph.D.
Chief Medical Officer, Gilead
Development of Treatments for the Globe: from HIV to COVID-19
 
Panel Discussion

Creating a Patient-driven, Science-first R&D Organization

Andrew Plump, MD, PhD
President, R&D, Takeda Pharmaceutical

Development of Treatments for the Globe: from HIV to COVID-19

Merdad Parsey, MD, PhD
Chief Medical Officer, Gilead

Panel Discussion

Moderator: Peter Kim, Ph.D.
Virginia and D.K. Ludwig Professor of Biochemistry, Stanford University

Co-Moderator: Kuldev Singh, M.D.
Professor of Ophthalmology, Stanford University School of Medicine

Speakers:

Andrew Plump, M.D., Ph.D.
President, Research & Development, Takeda Pharmaceutical

Aviv Regev, Ph.D.
Executive Vice President, Research and Early Development, Genentech

James Bradner, M.D.
President, Novartis Institutes of BioMedical Research

Merdad Parsey, M.D., Ph.D.
Chief Medical Officer, Gilead

Day 2 Closing Remarks

Joseph Wu, MD, PhD
Director, Stanford CVI
Simon H. Stertzer, MD, Professor, Department of Medicine and Radiology
Stanford University School of Medicine